Wenping Zhou

Wenping Zhou is currently an Associate at Vivo Capital, a healthcare-focused investment firm where she evaluates emerging biotechnology investments. She earned a PhD in Cell Biology from Yale University in 2020 and previously completed a BS degree at Nanjing University in 2013. Following her doctoral studies, Zhou initiated her finance career by serving as a Bioscience Investment Associate at Connecticut Innovations from 2020 to 2022. She subsequently transitioned into public market analysis, working as a Senior Research Associate at Evercore Group LLC between 2022 and 2023. Prior to joining Vivo Capital, she covered SMID-cap biotechnology equities as an Equity Research Associate at Cantor Fitzgerald and Company from 2023 to 2024. Zhou maintains a specialized focus on leveraging her advanced scientific background to assess complex healthcare assets across both private venture capital and public equity markets.